Novacyt Raises €784,736: Capital Increase Oversubscribed by 125%
Novacyt announced on March 20, 2026, the closure of its capital increase with preferential subscription rights, having raised €784,736 through the issuance of 1,961,840 new ordinary shares.
Details of the Capital Increase
The company raised €784,736 by issuing 1,961,840 New Shares at a unit price of €0.40. The total demand amounted to 2,456,286 New Shares, representing approximately 125.2% of the number of shares to be issued. The subscriptions on an irreducible basis reached 328,109 shares (€131,243.60), those on a reducible basis 592,383 shares (€236,953.20), and those on a free basis 1,535,794 shares (€614,317.60). The former owner of Southern Cross Diagnostics subscribed to 1,041,348 New Shares for an amount of €416,539.20. The service rate for free subscriptions was about 67.8% due to the oversubscription.
Allocation and Shareholder Impact
The Board of Directors allocated the 1,041,348 shares not absorbed by the irreducible and reducible subscriptions to Ardenna PTY Ltd, the former owner of Southern Cross Diagnostics, who now holds 1.43% of the capital. A retention agreement for a minimum duration of 12 months was signed with Ardenna PTY Ltd, followed by a 6-month abstention period governing the terms of sale. Following the settlement-delivery scheduled for March 24, 2026, the share capital will amount to €4,839,205.87 divided into 72,588,088 ordinary shares. The equity per share will change from €0.67 before the increase to €0.66 after (before deduction of expenses). A shareholder holding 1% before the increase would see their stake diluted to 0.97%.
